NextCure (NXTC) Expected to Announce Quarterly Earnings on Thursday

NextCure (NASDAQ:NXTC) is expected to release its Q1 2025 earnings data before the market opens on Thursday, May 1st. Analysts expect NextCure to post earnings of ($0.40) per share for the quarter.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.07). On average, analysts expect NextCure to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NextCure Stock Performance

NASDAQ NXTC opened at $0.49 on Wednesday. NextCure has a 52-week low of $0.22 and a 52-week high of $1.82. The company has a fifty day moving average of $0.53 and a 200-day moving average of $0.86. The company has a market capitalization of $13.83 million, a P/E ratio of -0.24 and a beta of 0.89.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of NextCure in a research note on Monday, March 17th.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.